logologologo

Intellectual Property focused on
Patents, Technology & Business

  • About the Firm
  • Team
    • Pedro Berkenwald
    • Alicia Alvarez Berkenwald
    • Anahí Cordero
    • Ernesto Machicote
    • Federico Ulled
    • Lucía Scarpati
    • Emilio Berkenwald
    • Elena R. Pérez
    • María Aurora García
    • Diego Federico Martin
    • Federico Maddonni Brito
    • Guadalupe Ocampo
  • Technology Areas
    • Biotechnology, Chemical & Pharmaceutical
    • Electronics and Information Technology
    • Industrial Chemistry and Mechanics
  • Services
    • Intellectual Property Prosecution
    • Legal Affairs
    • Patent Intelligence
  • Clients
    • Companies
    • Scientific Community
    • Associates
  • Blog
  • Contact Us
  • English
  • Spanish
logologologo

Intellectual Property focused on
Patents, Technology & Business

  • About the Firm
  • Team
    • Pedro Berkenwald
    • Alicia Alvarez Berkenwald
    • Anahí Cordero
    • Ernesto Machicote
    • Federico Ulled
    • Lucía Scarpati
    • Emilio Berkenwald
    • Elena R. Pérez
    • María Aurora García
    • Diego Federico Martin
    • Federico Maddonni Brito
    • Guadalupe Ocampo
  • Technology Areas
    • Biotechnology, Chemical & Pharmaceutical
    • Electronics and Information Technology
    • Industrial Chemistry and Mechanics
  • Services
    • Intellectual Property Prosecution
    • Legal Affairs
    • Patent Intelligence
  • Clients
    • Companies
    • Scientific Community
    • Associates
  • Blog
  • Contact Us
  • English
  • Spanish
logologologo

Intellectual Property focused on
Patents, Technology & Business

  • About the Firm
  • Team
    • Pedro Berkenwald
    • Alicia Alvarez Berkenwald
    • Anahí Cordero
    • Ernesto Machicote
    • Federico Ulled
    • Lucía Scarpati
    • Emilio Berkenwald
    • Elena R. Pérez
    • María Aurora García
    • Diego Federico Martin
    • Federico Maddonni Brito
    • Guadalupe Ocampo
  • Technology Areas
    • Biotechnology, Chemical & Pharmaceutical
    • Electronics and Information Technology
    • Industrial Chemistry and Mechanics
  • Services
    • Intellectual Property Prosecution
    • Legal Affairs
    • Patent Intelligence
  • Clients
    • Companies
    • Scientific Community
    • Associates
  • Blog
  • Contact Us
  • English
  • Spanish
logologologo

Intellectual Property focused on
Patents, Technology & Business

  • About the Firm
  • Team
    • Pedro Berkenwald
    • Alicia Alvarez Berkenwald
    • Anahí Cordero
    • Ernesto Machicote
    • Federico Ulled
    • Lucía Scarpati
    • Emilio Berkenwald
    • Elena R. Pérez
    • María Aurora García
    • Diego Federico Martin
    • Federico Maddonni Brito
    • Guadalupe Ocampo
  • Technology Areas
    • Biotechnology, Chemical & Pharmaceutical
    • Electronics and Information Technology
    • Industrial Chemistry and Mechanics
  • Services
    • Intellectual Property Prosecution
    • Legal Affairs
    • Patent Intelligence
  • Clients
    • Companies
    • Scientific Community
    • Associates
  • Blog
  • Contact Us
  • English
  • Spanish
logologologo

Intellectual Property focused on
Patents, Technology & Business

  • About the Firm
  • Team
    • Pedro Berkenwald
    • Alicia Alvarez Berkenwald
    • Anahí Cordero
    • Ernesto Machicote
    • Federico Ulled
    • Lucía Scarpati
    • Emilio Berkenwald
    • Elena R. Pérez
    • María Aurora García
    • Diego Federico Martin
    • Federico Maddonni Brito
    • Guadalupe Ocampo
  • Technology Areas
    • Biotechnology, Chemical & Pharmaceutical
    • Electronics and Information Technology
    • Industrial Chemistry and Mechanics
  • Services
    • Intellectual Property Prosecution
    • Legal Affairs
    • Patent Intelligence
  • Clients
    • Companies
    • Scientific Community
    • Associates
  • Blog
  • Contact Us
  • English
  • Spanish
logologologo

Intellectual Property focused on
Patents, Technology & Business

  • About the Firm
  • Team
    • Pedro Berkenwald
    • Alicia Alvarez Berkenwald
    • Anahí Cordero
    • Ernesto Machicote
    • Federico Ulled
    • Lucía Scarpati
    • Emilio Berkenwald
    • Elena R. Pérez
    • María Aurora García
    • Diego Federico Martin
    • Federico Maddonni Brito
    • Guadalupe Ocampo
  • Technology Areas
    • Biotechnology, Chemical & Pharmaceutical
    • Electronics and Information Technology
    • Industrial Chemistry and Mechanics
  • Services
    • Intellectual Property Prosecution
    • Legal Affairs
    • Patent Intelligence
  • Clients
    • Companies
    • Scientific Community
    • Associates
  • Blog
  • Contact Us
  • English
  • Spanish
  • About the Firm
  • Team
    • Pedro Berkenwald
    • Alicia Alvarez Berkenwald
    • Anahí Cordero
    • Ernesto Machicote
    • Federico Ulled
    • Lucía Scarpati
    • Emilio Berkenwald
    • Elena R. Pérez
    • María Aurora García
    • Diego Federico Martin
    • Federico Maddonni Brito
    • Guadalupe Ocampo
  • Technology Areas
    • Biotechnology, Chemical & Pharmaceutical
    • Electronics and Information Technology
    • Industrial Chemistry and Mechanics
  • Services
    • Intellectual Property Prosecution
    • Legal Affairs
    • Patent Intelligence
  • Clients
    • Companies
    • Scientific Community
    • Associates
  • Blog
  • Contact Us
  • English
  • Spanish
by Emilio Berkenwald
IP NewsJuly 7, 20200 comments 0 Likes

Personalized medicine and patents

Personalized medicine is based on the administration of active ingredients to individuals sharing a specific biological feature. It relates to targeted therapies that search for the most appropriate treatment for a given patient, and that are usually presented as the promising future of medicine.

In many cases, the active ingredients used in these treatments are known compounds. However, determining the effective doses and the population for which such administration is therapeutically effective may involve experimental developments, as well as considerable economic efforts. In this context, it is of interest to know whether this “personalized medical use” resulting from research can be protected by a patent.

In other words, is it possible to claim a compound X for the treatment of disease Y administered to patients that share feature Z or, alternatively, a treatment for disease Y comprising administering a compound X to patients that share feature Z?

Under the European patent system, the possibility of second medical uses claims is provided by Art 54(5) EPC. A medical use of a known compound X may confer novelty to a claim directed to compound X for the treatment of disease Y, as long as said treatment does not form part of the state of the art. If a related technical effect is demonstrated, the therapeutic indication may be considered as a functional feature of the claim, conferring novelty to the claim in accordance with decision G 2/88 of the Enlarged Board of Appeal.

Later on, in decision G 2/08 of 2010, the Enlarged Board stated that a new mode of administration or dosage regime of compound X, or even the treatment of the same disease Y in a new group of patients, could contribute to the novelty of a medical use even if the general use of compound X for the treatment of disease Y were already known. This decision also set forth the prohibition of “Swiss type” claims for second medical uses under the European system.

In 2019, decision T 694/16 of a Technical Board of Appeal reaffirmed these principles and extended them specifically to personalized medicine. The case at issue was related to a known compound for the treatment of dementia, where the use of such compound in patients presenting a specific biological marker detectable in cerebrospinal fluid was claimed. According to patent EP2170104, this marker allows to distinguish between patients in prodromal phase, who will develop dementia, and patients presenting cognitive symptoms but who will not necessarily develop dementia. For the Board of Appeal, the selection of a subgroup of patients based on a feature Z (the common biological marker) may contribute to the novelty of a personalized medicine claim: the functional relationship between markers that characterize patients and the therapeutic effect which is sought is an essential technical feature of the claim. Moreover, prior art describing the use of compound X for the treatment of a disease Y in a group of patients including the subgroup having feature Z does not inherently or inevitably disclose this functional relationship and does not affect novelty of the claim.

With this decision, the European Patent Office confirms that it is possible to obtain European patents related to personalized medicine, even if the general use of an active principle in a determined treatment is known in the state of the art. To obtain a valid patent, the personalized treatment must also meet the inventive step requirement, meaning that it must not be obviously derivable from the prior art.

In Argentina, according to a Joint Ministry Resolution issued by the Patent Office and the Ministry of Health in 2012, second medical uses are not deemed patentable: nowadays, personalized medicine may hardly be the object of a patent of invention, regardless of whether novelty and inventive step criteria are met. Other Latin American countries accept second medical uses, as long as they are claimed according to local practice and all other patentability requirements are met.

In general, claims directed to uses are not accepted in the United States, although therapeutic methods for treatment are permitted. Nonetheless, the doctrine of inherency and anticipation practice under the US patent system may make it difficult to protect personalized medicine as compared to the European system.

Share

Emilio Berkenwald

Emilio is a patent engineer specialized in the fields of chemistry, industrial chemistry and materials engineering. He is involved in patent drafting, translation, filing and prosecution of patent application of domestic and foreign clients in Argentina and Latin America.
Leaders League 2020 RankingPrev
WIPO PROOF: new “digital fingerprint”Next

Latest Posts

by Diego Federico Martin

Patentability of polymorphs in Argentina: some thoughts in the light of recent rulings

On December 16, 2021, and May 3, 2022, Division I of the Argentine Federal Court in Civil and Commercial matters rendered two separate rulings – PFIZER...

Patentability of polymorphs in Argentina: some thoughts in the light of recent rulings

General interestJanuary 12, 2023
Share
by BERKEN IP

ASIPI Meeting 2022

Our Partners Alicia Alvarez Berkenwald and María Aurora García will participate in ASIPI’s XXIII Jornadas de Trabajo y Consejo de Administración that will...

ASIPI Meeting 2022

IP AssociationsNovember 30, 2022
Share

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

Recent posts

  • Patentability of polymorphs in Argentina: some thoughts in the light of recent rulings
  • ASIPI Meeting 2022
  • Alicia Alvarez-Berkenwald listed in IAM Global Leaders 2023
  • INTA’s Leadership Meeting at Miami
  • Emilio Berkenwald at AIPLA 2022

Archive

  • January 2023
  • November 2022
  • October 2022
  • September 2022
  • July 2022
  • May 2022
  • April 2022
  • November 2021
  • October 2021
  • September 2021
  • July 2021
  • May 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • February 2019

Categories

  • BERKEN IP News
  • Biotechnology
  • General interest
  • International Publications
  • IP Associations
  • IP News
  • IP Training
  • Regulatory Affairs

Tags

AIPLA aippi Argentine ASIPI ASIPI2022 bayarea brands Ceipi CEIPIDroitComparé chambersandpartners chamberslatam chamberslatinamerica confinement2 congress covid-19 ficpi germany grur IAM IAMGlobalLeaders IAMPatent1000 inpi INTA INTAconnect INTALM intellectualproperty IP ip law patent Patents PI Strasbourg trademarks Unista USPTO WIPNE wipo WomeninIP
logo

BERKEN IP is an Intellectual Property Law Firm focused on Patents, Technology & Business, located in Buenos Aires, Argentina.

Quick menu

  • About the Firm
  • Team
  • Services

Services

  • Intellectual Property Prosecution
  • Legal Affairs
  • Patent Intelligence

Technology Areas

  • – Biotechnology, Chemical & Pharmaceutical
  • – Electronics and Information Technology
  • – Industrial Chemistry and Mechanics

Contact us

  • Email
  • Map
  • Twitter
  • LinkedIn

© 2020 BERKEN IP. All rights reserved | Legal Notice | Personal Data Policy